RP5063 + placebo + aripiprazole
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Schizophrenia
Conditions
Acute Schizophrenia, Schizoaffective Disorder
Trial Timeline
Dec 1, 2011 → Mar 1, 2013
NCT ID
NCT01490086About RP5063 + placebo + aripiprazole
RP5063 + placebo + aripiprazole is a phase 2 stage product being developed by Reviva Pharmaceuticals for Acute Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT01490086. Target conditions include Acute Schizophrenia, Schizoaffective Disorder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01490086 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Schizophrenia